KIF3C: A Potential Drug Target for KiNDo (G3797)

Target Name: KIF3C

NCBI ID: G3797

KIF3C: A Potential Drug Target for KiNDo

Kinesin Family Member 3C (KIF3C) is a protein that plays a critical role in the structure and function of the mitochondria, which are responsible for generating energy in the cell. Mutations in the KIF3C gene have been linked to a range of cardiovascular and neurological disorders , making it an attractive drug target for researchers. In this article, we will explore the biological and medical implications of KIF3C and its potential as a drug.

The KIF3C gene is located on chromosome 16 and encodes a protein that is composed of 115 amino acid residues. The protein has a molecular weight of 13.9 kDa and a pre-protein N-terminal extension of 14 amino acids. KIF3C is a member of the Kinesin family, which includes a group of proteins that are involved in the proper functioning of mitochondria. The Kinesin family plays a crucial role in the transfer of mitochondrial DNA to the cytoplasm in eukaryotic cells.

Mutations in the KIF3C gene have been linked to a range of cardiovascular and neurological disorders, including heart failure, cardiomyopathy, and neurodegenerative diseases. The most well-known mutation is a missense mutation, which has been shown to cause a progressive neurodegenerative disorder called KIF3C-related neurodegeneration (KiNDo).

KiNDo is a neurodegenerative disorder that is characterized by the progressive loss of brain cells, which can result in a range of cognitive and motor deficits. The symptoms of KiNDo are similar to those of other neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The progressive The nature of the disease makes it difficult to diagnose, and the exact cause is not always known. However, studies have shown that KiNDo is caused by a genetic mutation, specifically a missense mutation in the KIF3C gene.

The KiNDo mouse is a well-established model for the study of neurodegenerative diseases, and has been used to study the effects of various drugs on the progression of KiNDo. One of the most promising drugs that has been shown to slow down the progression of KiNDo is a drug called \"TX-501\". This drug is a small molecule that inhibits the activity of a protein called TIPP, which is a phospholipid that can cause the build-up of toxic substances in the brain.

TX-501 has been shown to slow down the progression of KiNDo in both mouse and human models of the disease. In addition, TX-501 has been shown to protect against neurotoxicity in KiNDo-simulated mice, by reducing the level of toxic substances in their brains.

Another drug that is being studied for its potential to treat KiNDo is \"CP-1022\". This drug is a small molecule that inhibits the activity of a protein called FAT/NAD+-dependent protein kinase (FNK), which is involved in the production of reactive oxygen species (ROS) in the brain. ROS are known to contribute to the damage caused by neurodegenerative diseases, and the development of TX-501 has shown that it can protect against ROS in the brain.

CP-1022 has been shown to slow down the progression of KiNDo in both mouse and human models of the disease. In addition, CP-1022 has been shown to increase the levels of a protein called Bcl-2, which can help protect against neurotoxicity in KiNDo-mock mice.

In addition to these drugs, researchers are also studying the potential of other small molecules and natural compounds to treat KiNDo. For example, a compound called \"Q-178\" has been shown to slow down the progression of KiNDo in mouse models of the disease. In addition, a compound called \"

Protein Name: Kinesin Family Member 3C

Functions: Microtubule-based anterograde translocator for membranous organelles

More Common Targets